Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

H. S. Rugo, R. S. Finn, V. Diéras, J. Ettl, O. Lipatov, A. A. Joy, N. Harbeck, A. Castrellon, S. Iyer, D. R. Lu, A. Mori, E. R. Gauthier, C. Huang Bartlett, K. A. Gelmon, D. J. Slamon

ABSTRACT

PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. METHODS: In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). RESULTS: After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. CONCLUSIONS: With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427. More... »

PAGES

719-729

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-018-05125-4

DOI

http://dx.doi.org/10.1007/s10549-018-05125-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111320245

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30632023


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, 94115, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rugo", 
        "givenName": "H. S.", 
        "id": "sg:person.01206651255.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206651255.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California Los Angeles", 
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finn", 
        "givenName": "R. S.", 
        "id": "sg:person.01000523143.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000523143.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Eug\u00e8ne Marquis", 
          "id": "https://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Department of Medical Oncology, Institut Curie, Paris, France", 
            "Centre Eug\u00e8ne Marquis, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di\u00e9ras", 
        "givenName": "V.", 
        "id": "sg:person.01104241537.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104241537.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Technical University Munich", 
          "id": "https://www.grid.ac/institutes/grid.6936.a", 
          "name": [
            "Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ettl", 
        "givenName": "J.", 
        "id": "sg:person.01273246550.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273246550.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lipatov", 
        "givenName": "O.", 
        "id": "sg:person.01170463040.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170463040.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Alberta", 
          "id": "https://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joy", 
        "givenName": "A. A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Maximilian University of Munich", 
          "id": "https://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Department of Obstetrics and Gynecology, Brustzentrum der Universit\u00e4t M\u00fcnchen (LMU), Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harbeck", 
        "givenName": "N.", 
        "id": "sg:person.0735450544.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735450544.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Long Beach Memorial Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.415304.7", 
          "name": [
            "Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castrellon", 
        "givenName": "A.", 
        "id": "sg:person.01351513227.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351513227.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Patient and Health Impact, Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iyer", 
        "givenName": "S.", 
        "id": "sg:person.01127017007.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127017007.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Clinical Statistics, Pfizer Inc, La Jolla, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "D. R.", 
        "id": "sg:person.0605257105.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605257105.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mori", 
        "givenName": "A.", 
        "id": "sg:person.014326356325.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014326356325.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gauthier", 
        "givenName": "E. R.", 
        "id": "sg:person.012245243625.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012245243625.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bartlett", 
        "givenName": "C. Huang", 
        "id": "sg:person.0644331036.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644331036.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gelmon", 
        "givenName": "K. A.", 
        "id": "sg:person.01173252503.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California Los Angeles", 
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Slamon", 
        "givenName": "D. J.", 
        "id": "sg:person.0736251043.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736251043.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1607303", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005496514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.67.1487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010471013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)32389-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014303949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1505270", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016758516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.56.7479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033358604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0168-8510(90)90421-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033898358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-009-0310-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038486754", 
          "https://doi.org/10.1007/s10549-009-0310-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-009-0310-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038486754", 
          "https://doi.org/10.1007/s10549-009-0310-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.3524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039426670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1609709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045557388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2016.10.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046767167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71159-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053530404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.73.7585", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085860547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.75.6155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092051908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100523703"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23\u00a0months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P\u2009<\u20090.001]. Herein, we report results overall and by subgroups with extended follow-up.\nMETHODS: In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs).\nRESULTS: After a median follow-up of approximately 38\u00a0months, median PFS was 27.6\u00a0months for palbociclib-letrozole (n\u2009=\u2009444) and 14.5\u00a0months for placebo-letrozole (n\u2009=\u2009222) (HR 0.563; 1-sided P\u2009<\u20090.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9\u00a0months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained.\nCONCLUSIONS: With approximately 15\u00a0months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-018-05125-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "174"
      }
    ], 
    "name": "Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up", 
    "pagination": "719-729", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "602271c5c19d404adf2d1808fd7b4df1ac435725f89ab2d39eea11b9c7d83d63"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30632023"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-018-05125-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111320245"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-018-05125-4", 
      "https://app.dimensions.ai/details/publication/pub.1111320245"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78944_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10549-018-05125-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-018-05125-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-018-05125-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-018-05125-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-018-05125-4'


 

This table displays all metadata directly associated to this object as RDF triples.

245 TRIPLES      21 PREDICATES      44 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-018-05125-4 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nc3426e3d37ff435e8736f4773fe15bbf
4 schema:citation sg:pub.10.1007/s10549-009-0310-8
5 https://doi.org/10.1002/sim.3524
6 https://doi.org/10.1016/0168-8510(90)90421-9
7 https://doi.org/10.1016/j.breast.2016.10.001
8 https://doi.org/10.1016/s0140-6736(16)32389-3
9 https://doi.org/10.1016/s1470-2045(14)71159-3
10 https://doi.org/10.1056/nejmoa1505270
11 https://doi.org/10.1056/nejmoa1607303
12 https://doi.org/10.1056/nejmoa1609709
13 https://doi.org/10.1093/annonc/mdy012
14 https://doi.org/10.1200/jco.1997.15.3.974
15 https://doi.org/10.1200/jco.2014.56.7479
16 https://doi.org/10.1200/jco.2016.67.1487
17 https://doi.org/10.1200/jco.2017.73.7585
18 https://doi.org/10.1200/jco.2017.75.6155
19 schema:datePublished 2019-04
20 schema:datePublishedReg 2019-04-01
21 schema:description PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. METHODS: In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). RESULTS: After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. CONCLUSIONS: With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.
22 schema:genre research_article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N15b2bd37e3274204904c60278c24c077
26 N218fe95e649c4ff3a4fb5a76580a5152
27 sg:journal.1092777
28 schema:name Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
29 schema:pagination 719-729
30 schema:productId N0a3d3970c4074c28a1d13618e819b268
31 N1db6381c104e4b2e9ead4419b91d944a
32 N3c06f374a37c40e1b0f4478248345439
33 Na6fddf417caf4225bc7550f7141943a7
34 Nc1852d47b8b54715ae6762279e15e007
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111320245
36 https://doi.org/10.1007/s10549-018-05125-4
37 schema:sdDatePublished 2019-04-11T13:18
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher Ne559d647f81349a4a6449601c33db705
40 schema:url https://link.springer.com/10.1007%2Fs10549-018-05125-4
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N02fd0686bdb54169a05dcfb6ead9138d schema:name Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA
45 rdf:type schema:Organization
46 N085ef8b008ba4e67a80bf76363927d3c rdf:first sg:person.01351513227.34
47 rdf:rest Nabdfab126a6a42299280dd073fd84de1
48 N0a3d3970c4074c28a1d13618e819b268 schema:name dimensions_id
49 schema:value pub.1111320245
50 rdf:type schema:PropertyValue
51 N15b2bd37e3274204904c60278c24c077 schema:issueNumber 3
52 rdf:type schema:PublicationIssue
53 N15d02fc0f6ae4b73a00870d162abc420 rdf:first sg:person.01273246550.33
54 rdf:rest N8de3343f939b43ed9532a335145404d6
55 N1930c91d445b40c28b28fb6b800bc0f6 rdf:first Nb2259b7c00b041a4ad09482fb8a2d265
56 rdf:rest N770c4a53edc14099af89dee8563f21da
57 N1db6381c104e4b2e9ead4419b91d944a schema:name readcube_id
58 schema:value 602271c5c19d404adf2d1808fd7b4df1ac435725f89ab2d39eea11b9c7d83d63
59 rdf:type schema:PropertyValue
60 N218fe95e649c4ff3a4fb5a76580a5152 schema:volumeNumber 174
61 rdf:type schema:PublicationVolume
62 N3a61a6c1ac5b4ccb81a421364c07cb9a rdf:first sg:person.0605257105.79
63 rdf:rest Nd611d4bcc22a4f03910df00ea31d37cd
64 N3c06f374a37c40e1b0f4478248345439 schema:name doi
65 schema:value 10.1007/s10549-018-05125-4
66 rdf:type schema:PropertyValue
67 N4c3976bc42e148f9a461d4527398c8a7 schema:name Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy
68 rdf:type schema:Organization
69 N655c24d865c44777a6cafb6d3ba5dbb3 rdf:first sg:person.01104241537.43
70 rdf:rest N15d02fc0f6ae4b73a00870d162abc420
71 N770c4a53edc14099af89dee8563f21da rdf:first sg:person.0735450544.81
72 rdf:rest N085ef8b008ba4e67a80bf76363927d3c
73 N7d33cc6fee574e7fbdf40389339effb2 rdf:first sg:person.01173252503.80
74 rdf:rest Ncd2ec137b837476ba47416ff5b1cddfe
75 N7fa0299053054e14a7760dfcdf750cb3 schema:name Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia
76 rdf:type schema:Organization
77 N7fd9550d848344f2929c58d23830c3c6 rdf:first sg:person.01000523143.79
78 rdf:rest N655c24d865c44777a6cafb6d3ba5dbb3
79 N8de3343f939b43ed9532a335145404d6 rdf:first sg:person.01170463040.04
80 rdf:rest N1930c91d445b40c28b28fb6b800bc0f6
81 Na2f312667ec34aabb146510cadfd39c5 rdf:first sg:person.0644331036.39
82 rdf:rest N7d33cc6fee574e7fbdf40389339effb2
83 Na6fddf417caf4225bc7550f7141943a7 schema:name pubmed_id
84 schema:value 30632023
85 rdf:type schema:PropertyValue
86 Nabdfab126a6a42299280dd073fd84de1 rdf:first sg:person.01127017007.95
87 rdf:rest N3a61a6c1ac5b4ccb81a421364c07cb9a
88 Nb2259b7c00b041a4ad09482fb8a2d265 schema:affiliation https://www.grid.ac/institutes/grid.17089.37
89 schema:familyName Joy
90 schema:givenName A. A.
91 rdf:type schema:Person
92 Nc1852d47b8b54715ae6762279e15e007 schema:name nlm_unique_id
93 schema:value 8111104
94 rdf:type schema:PropertyValue
95 Nc3426e3d37ff435e8736f4773fe15bbf rdf:first sg:person.01206651255.06
96 rdf:rest N7fd9550d848344f2929c58d23830c3c6
97 Nc52f62a9b189410d8cae0e4027e51e4d rdf:first sg:person.012245243625.29
98 rdf:rest Na2f312667ec34aabb146510cadfd39c5
99 Ncd2ec137b837476ba47416ff5b1cddfe rdf:first sg:person.0736251043.00
100 rdf:rest rdf:nil
101 Nd611d4bcc22a4f03910df00ea31d37cd rdf:first sg:person.014326356325.52
102 rdf:rest Nc52f62a9b189410d8cae0e4027e51e4d
103 Ne559d647f81349a4a6449601c33db705 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
106 schema:name Medical and Health Sciences
107 rdf:type schema:DefinedTerm
108 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
109 schema:name Oncology and Carcinogenesis
110 rdf:type schema:DefinedTerm
111 sg:journal.1092777 schema:issn 0167-6806
112 1573-7217
113 schema:name Breast Cancer Research and Treatment
114 rdf:type schema:Periodical
115 sg:person.01000523143.79 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
116 schema:familyName Finn
117 schema:givenName R. S.
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000523143.79
119 rdf:type schema:Person
120 sg:person.01104241537.43 schema:affiliation https://www.grid.ac/institutes/grid.417988.b
121 schema:familyName Diéras
122 schema:givenName V.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104241537.43
124 rdf:type schema:Person
125 sg:person.01127017007.95 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
126 schema:familyName Iyer
127 schema:givenName S.
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127017007.95
129 rdf:type schema:Person
130 sg:person.01170463040.04 schema:affiliation N7fa0299053054e14a7760dfcdf750cb3
131 schema:familyName Lipatov
132 schema:givenName O.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170463040.04
134 rdf:type schema:Person
135 sg:person.01173252503.80 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
136 schema:familyName Gelmon
137 schema:givenName K. A.
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80
139 rdf:type schema:Person
140 sg:person.01206651255.06 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
141 schema:familyName Rugo
142 schema:givenName H. S.
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206651255.06
144 rdf:type schema:Person
145 sg:person.012245243625.29 schema:affiliation N02fd0686bdb54169a05dcfb6ead9138d
146 schema:familyName Gauthier
147 schema:givenName E. R.
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012245243625.29
149 rdf:type schema:Person
150 sg:person.01273246550.33 schema:affiliation https://www.grid.ac/institutes/grid.6936.a
151 schema:familyName Ettl
152 schema:givenName J.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273246550.33
154 rdf:type schema:Person
155 sg:person.01351513227.34 schema:affiliation https://www.grid.ac/institutes/grid.415304.7
156 schema:familyName Castrellon
157 schema:givenName A.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351513227.34
159 rdf:type schema:Person
160 sg:person.014326356325.52 schema:affiliation N4c3976bc42e148f9a461d4527398c8a7
161 schema:familyName Mori
162 schema:givenName A.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014326356325.52
164 rdf:type schema:Person
165 sg:person.0605257105.79 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
166 schema:familyName Lu
167 schema:givenName D. R.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605257105.79
169 rdf:type schema:Person
170 sg:person.0644331036.39 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
171 schema:familyName Bartlett
172 schema:givenName C. Huang
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644331036.39
174 rdf:type schema:Person
175 sg:person.0735450544.81 schema:affiliation https://www.grid.ac/institutes/grid.5252.0
176 schema:familyName Harbeck
177 schema:givenName N.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735450544.81
179 rdf:type schema:Person
180 sg:person.0736251043.00 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
181 schema:familyName Slamon
182 schema:givenName D. J.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736251043.00
184 rdf:type schema:Person
185 sg:pub.10.1007/s10549-009-0310-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038486754
186 https://doi.org/10.1007/s10549-009-0310-8
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1002/sim.3524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039426670
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1016/0168-8510(90)90421-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033898358
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1016/j.breast.2016.10.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046767167
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1016/s0140-6736(16)32389-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014303949
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1016/s1470-2045(14)71159-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053530404
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1056/nejmoa1505270 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016758516
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1056/nejmoa1607303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005496514
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1056/nejmoa1609709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045557388
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1093/annonc/mdy012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100523703
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1200/jco.1997.15.3.974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057211
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1200/jco.2014.56.7479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033358604
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.2016.67.1487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010471013
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1200/jco.2017.73.7585 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085860547
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1200/jco.2017.75.6155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092051908
215 rdf:type schema:CreativeWork
216 https://www.grid.ac/institutes/grid.17089.37 schema:alternateName University of Alberta
217 schema:name Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.19006.3e schema:alternateName University of California Los Angeles
220 schema:name Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
223 schema:name Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
226 schema:name Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, 94115, San Francisco, CA, USA
227 rdf:type schema:Organization
228 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
229 schema:name Clinical Statistics, Pfizer Inc, La Jolla, CA, USA
230 Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA
231 Patient and Health Impact, Pfizer Inc, New York, NY, USA
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.415304.7 schema:alternateName Long Beach Memorial Medical Center
234 schema:name Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.417988.b schema:alternateName Centre Eugène Marquis
237 schema:name Centre Eugène Marquis, Rennes, France
238 Department of Medical Oncology, Institut Curie, Paris, France
239 rdf:type schema:Organization
240 https://www.grid.ac/institutes/grid.5252.0 schema:alternateName Ludwig Maximilian University of Munich
241 schema:name Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany
242 rdf:type schema:Organization
243 https://www.grid.ac/institutes/grid.6936.a schema:alternateName Technical University Munich
244 schema:name Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany
245 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...